Predictors for thyroid dysfunction after discontinuation of levothyroxine in children and adolescents with Hashimoto thyroiditis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Few data on the clinical course after levothyroxine (L-T4) discontinuation in pediatric patients with Hashimoto thyroiditis (HT) are available. We investigated outcomes and predictors for successful withdrawal from L-T4 among children with HT.Methods: Among 168 patients diagnosed with HT between January 2000 and March 2021 at Seoul National University Children’s Hospital and in whom L-T4 therapy was initiated during childhood, we attempted to discontinue this therapy in 47, 3 boys and 44 girls. L-T4 was restarted when patients developed overt or subclinical hypothyroidism (thyroid-stimulating hormone [TSH] levels≥10 mIU/L) after L-T4 discontinuation.Results: Median age at discontinuation was 15.4 years (12.7–18.4 years) with a median duration of L-T4 therapy of 47 months (20.3–80.3 months). During the median 30 months of follow-up (10.6–61.0 months) after L-T4 discontinuation, 33 (70.2%) developed thyroid dysfunction. Among these patients, 17 were eventually restarted on L-T4. TSH levels over 50 mIU/L at L-T4 initiation (hazard ratio, HR 3.5, P=0.002), age under 12 years at L-T4 discontinuation (HR 11.1, P=0.0001), and TSH levels higher than the upper 50% of normal (above 2.25 mIU/L in the present study) at L-T4 discontinuation (HR 2.7, P=0.014) were significantly predictive for overt hypothyroidism or subclinical hypothyroidism after L-T4 discontinuation. In addition, age under 12 years at L-T4 discontinuation was only predictive factor for restarting L-T4 medication (HR 4.3, P=0.012).Conclusion: L-T4 discontinuation in pediatric patients with HT resulted in thyroid dysfunction in 70.2% of cases; 36.2% of patients who attempted discontinuation required resumption of L-T4. Older age and lower TSH levels at L-T4 discontinuation were advantageous for successful withdrawal.
Abstract
Purpose: Few data on the clinical course after levothyroxine (L-T4) discontinuation in pediatric patients with Hashimoto thyroiditis (HT) are available. We investigated outcomes and predictors for successful withdrawal from L-T4 among children with HT.Methods: Among 168 patients diagnosed with HT between January 2000 and March 2021 at Seoul National University Children’s Hospital and in whom L-T4 therapy was initiated during childhood, we attempted to discontinue this therapy in 47, 3 boys and 44 girls. L-T4 was restarted when patients developed overt or subclinical hypothyroidism (thyroid-stimulating hormone [TSH] levels≥10 mIU/L) after L-T4 discontinuation.Results: Median age at discontinuation was 15.4 years (12.7–18.4 years) with a median duration of L-T4 therapy of 47 months (20.3–80.3 months). During the median 30 months of follow-up (10.6–61.0 months) after L-T4 discontinuation, 33 (70.2%) developed thyroid dysfunction. Among these patients, 17 were eventually restarted on L-T4. TSH levels over 50 mIU/L at L-T4 initiation (hazard ratio, HR 3.5, P=0.002), age under 12 years at L-T4 discontinuation (HR 11.1, P=0.0001), and TSH levels higher than the upper 50% of normal (above 2.25 mIU/L in the present study) at L-T4 discontinuation (HR 2.7, P=0.014) were significantly predictive for overt hypothyroidism or subclinical hypothyroidism after L-T4 discontinuation. In addition, age under 12 years at L-T4 discontinuation was only predictive factor for restarting L-T4 medication (HR 4.3, P=0.012).Conclusion: L-T4 discontinuation in pediatric patients with HT resulted in thyroid dysfunction in 70.2% of cases; 36.2% of patients who attempted discontinuation required resumption of L-T4. Older age and lower TSH levels at L-T4 discontinuation were advantageous for successful withdrawal.
참고문헌 (16)
- Akamizu T, "Endotext" (2000), MDText.com, Inc
- Penta L, "Hashimoto's disease and thyroid cancer in children: are they associated?", Front Endocrinol (Lausanne), 9, pp.565~ (2018)
- Demirbilek H, "Assessment of thyroid function during the long course of Hashimoto's thyroiditis in children and adolescents", Clin Endocrinol, 71, pp.451~454 (2009)
- Wasniewska M, "Thyroid function patterns at Hashimoto’s thyroiditis presentation in childhood and adolescence are mainly conditioned by patients’ age", Horm Res Paediatr, 78, pp.232~236 (2012)
- Lazarus J, "2014 European thyroid association guidelines for the management of subclinical hypothyroidism in pregnancy and in children", Eur Thyroid J, 3, pp.76~94 (2014)
- Kaplowitz PB, "Subclinical hypothyroidism in children : normal variation or sign of a failing thyroid gland?", Int J Pediatr Endocrinol, 2010, pp.281453~ (2010)
- Lee YJ, "Unfavorable course of subclinical hypothyroidism in children with Hashimoto’s thyroiditis compared to those with isolated non-autoimmune hyperthyrotropinemia", J Korean Med Scie, 32, pp.124~ (2017)
- Aversa T, "Underlying Hashimoto's thyroiditis negatively affects the evolution of subclinical hypothyroidism in children irrespective of other concomitant risk factors", Thyroid, 25, pp.183~187 (2015)
- Lee HS, "The natural course of Hashimoto's thyroiditis in children and adolescents", J Pediatr Endocrinol Metab, 27, pp.807~812 (2014)
- Radetti G, "Thyroid function in children and adolescents with Hashimoto's thyroiditis after l-thyroxine discontinuation", Endocr Connect, 6, pp.206~212 (2017)
- Burgos N, "Clinical outcomes after discontinuation of thyroid hormone replacement : a systematic review and meta-analysis", Thyroid, 31, pp.740~751 (2021)
- Jung KY, "Clinical factors predicting the successful discontinuation of hormone replacement therapy in patients diagnosed with primary hypothyroidism", PLoS One, 15, pp.e0233596~ (2020)
- Takasu N, "Test for recovery from hypothyroidism during thyroxine therapy in Hashimoto's thyroiditis", Lancet, 336, pp.1084~1086 (1990)
- Caturegli P, "Hashimoto thyroiditis : clinical and diagnostic criteria", Autoimmun Rev, 13, pp.391~397 (2014)
- Kim JH, "The 2017 Korean National Growth Charts for children and adolescents : development, improvement, and prospects", Korean J Pediatr, 61, pp.135~149 (2018)
- Salerno M, "Management of endocrine disease subclinical hypothyroidism in children", Eur J Endocrinol, 183, pp.R13~R28 (2020)